[go: up one dir, main page]

MXPA03007853A - Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos. - Google Patents

Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos.

Info

Publication number
MXPA03007853A
MXPA03007853A MXPA03007853A MXPA03007853A MXPA03007853A MX PA03007853 A MXPA03007853 A MX PA03007853A MX PA03007853 A MXPA03007853 A MX PA03007853A MX PA03007853 A MXPA03007853 A MX PA03007853A MX PA03007853 A MXPA03007853 A MX PA03007853A
Authority
MX
Mexico
Prior art keywords
dideoxy
halonucleoside
haloacylation
bgr
didehydro
Prior art date
Application number
MXPA03007853A
Other languages
English (en)
Inventor
N Confalone Pasquale
Original Assignee
Pharmasset Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd filed Critical Pharmasset Ltd
Publication of MXPA03007853A publication Critical patent/MXPA03007853A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion es una ruta de sintesis eficiente para 2',3'-didesoxi-2',3'- dideshidro-nucleosidos a partir de precursores disponibles con la opcion de introducir grupos funcionales segun se necesite, tales como los analogos 2',3'-didesoxi y 2'- o 3'- desoxirribonucleosido asi como los derivados adicionales obtenidos por manipulaciones subsiguientes de grupo funcional. En breve, la presente invencion describe un metodo para preparar '-D- y '-L-2',3'-didesoxi-2',3'-dideshideshidro-nucleosidos partiendo de los ribonucleosidos sustituidos apropiadamente en dos, opcionalmente en tres pasos: Paso (1) una halogenoacilacion, tal como halogenoacetilacion, y en particular, bromoacetilacion; Paso (2) una eliminacion reductiva; y opcionalmente, Paso (3) una desproteccion. La halogenoacilacion del paso (1) puede formar el 2'-acil-3'-halogenonucleosido, el 3'-acil-2'-halogenonucleosido, o una mezcla de los mismos.
MXPA03007853A 2001-03-01 2002-03-01 Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos. MXPA03007853A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27243401P 2001-03-01 2001-03-01
US27244101P 2001-03-01 2001-03-01
PCT/US2002/006460 WO2002070533A2 (en) 2001-03-01 2002-03-01 Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides

Publications (1)

Publication Number Publication Date
MXPA03007853A true MXPA03007853A (es) 2004-05-24

Family

ID=26955519

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007853A MXPA03007853A (es) 2001-03-01 2002-03-01 Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos.

Country Status (13)

Country Link
US (2) US6927291B2 (es)
EP (1) EP1363927A2 (es)
JP (1) JP2004527504A (es)
KR (1) KR20030092006A (es)
CN (1) CN1505635A (es)
AU (1) AU2002255654B2 (es)
BR (1) BR0207746A (es)
CA (1) CA2439836A1 (es)
IL (1) IL157478A0 (es)
MX (1) MXPA03007853A (es)
NZ (1) NZ540956A (es)
RU (1) RU2003129164A (es)
WO (1) WO2002070533A2 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079246A2 (en) 2000-04-13 2001-10-25 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
SG174624A1 (en) 2002-08-01 2011-10-28 Pharmasset Inc Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
EP2319853B1 (en) 2002-12-12 2014-03-12 IDENIX Pharmaceuticals, Inc. Process for the production of 2'-branched nucleosides
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
CA2634749C (en) 2005-12-23 2014-08-19 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
MX2008009022A (es) * 2006-01-13 2008-09-24 Wyeth Corp 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina.
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
ATE525068T1 (de) 2007-02-28 2011-10-15 Conatus Pharmaceuticals Inc Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
WO2009020480A2 (en) * 2007-04-26 2009-02-12 The Scripps Research Institute Genomic mutation inhibitors that inhibit y family dna polymerases
AU2009277172B2 (en) * 2008-07-02 2014-05-29 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
CA2795054A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
FR2978441A1 (fr) * 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852603B1 (en) 2012-05-22 2021-05-12 Idenix Pharmaceuticals LLC D-amino acid compounds for liver disease
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AU2013329521B2 (en) 2012-10-08 2018-04-19 Centre National De La Recherche Scientifique 2'-chloro nucleoside analogs for HCV infection
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
CN103936637B (zh) * 2013-01-18 2016-04-06 北京大学 E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
LT3041854T (lt) 2013-08-08 2020-03-25 The Scripps Research Institute Nukleorūgščių specifinės vietos žymėjimo fermentais in vitro būdas, įvedant nenatūralius nukleotidus
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10683321B2 (en) 2013-12-18 2020-06-16 Idenix Pharmaceuticals Llc 4′-or nucleosides for the treatment of HCV
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
TWI638047B (zh) 2014-04-09 2018-10-11 史基普研究協會 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
HUE060123T2 (hu) 2016-06-24 2023-01-28 Scripps Research Inst Új nukleozid-trifoszfát-transzporter és alkalmazásai
EP3651774A4 (en) 2017-07-11 2021-07-07 The Scripps Research Institute INTEGRATION OF INNATURAL NUCLEOTIDES AND APPLICATION METHODS IN VIVO
KR20250171416A (ko) 2017-07-11 2025-12-08 신톡스, 인크. 비천연 뉴클레오티드의 도입 및 그의 방법
BR112020002272A2 (pt) 2017-08-03 2020-07-28 Synthorx, Inc. conjugados de citocina para o tratamento de doenças autoimunes
CN112105627B (zh) 2017-12-29 2024-07-02 斯克利普斯研究所 非天然碱基对组合物及使用方法
TWI834636B (zh) 2018-02-26 2024-03-11 美商欣爍克斯公司 Il-15結合物及其用途
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
US20200246467A1 (en) 2019-02-06 2020-08-06 Synthorx, Inc. Il-2 conjugates and methods of use thereof
JP7728181B2 (ja) 2019-06-14 2025-08-22 ザ スクリプス リサーチ インスティテュート 半合成生物における複製、転写および翻訳のための試薬ならびに方法
BR112022003046A8 (pt) 2019-08-23 2024-02-06 Synthorx Inc Conjugado de il-15, seu método de preparo e seus usos, bem como composição farmacêutica e método in vitro de expansão de uma ou mais das populações de células t
EP4028060A1 (en) 2019-09-10 2022-07-20 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817982A (en) 1971-12-29 1974-06-18 Syntex Inc 2{40 ,3{40 -unsaturated nucleosides and method of making
US4594339A (en) 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US5455339A (en) 1986-05-01 1995-10-03 University Of Georgia Research Foundation, Inc. Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides
JPS6339893A (ja) 1986-08-05 1988-02-20 Daikin Ind Ltd ５−フルオロウリジン類およびその製法
US5384396A (en) 1988-02-23 1995-01-24 The University Of Georgia Research Foundation, Inc. Process for the deoxygenation of nucleosides
US4904770A (en) 1988-03-24 1990-02-27 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
US4900828A (en) 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
US4987224A (en) 1988-08-02 1991-01-22 University Of Georgia Research Foundation, Inc. Method of preparation of 2',3'-dideoxynucleosides
NL8901258A (nl) 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
DD293498A5 (de) 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US5212298A (en) 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5200514A (en) 1990-01-19 1993-04-06 University Of Georgia Research Foundation, Inc. Synthesis of 2'-deoxypyrimidine nucleosides
US5175267A (en) 1990-03-02 1992-12-29 University Of Georgia Research Foundation, Inc. Stereoselective glycosylation of hetercyclic bases
FR2674064B1 (fr) * 1991-03-13 1993-06-04 Alsthom Gec Dispositif de varistance et de resistance pour la chambre de coupure d'un disjoncteur.
JPH04295475A (ja) * 1991-03-22 1992-10-20 Japan Tobacco Inc ２’，３’−ジデオキシ−２’，３’−　ジデヒドロヌクレオシド類の製法
JP3042073B2 (ja) 1991-06-19 2000-05-15 味の素株式会社 ヌクレオシド誘導体とその製造方法
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5539099A (en) 1993-11-15 1996-07-23 Bristol-Myers Squibb Company Process for large-scale preparation of 2',3'-didehydro-2',3'-dideoxynucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
MXPA00008348A (es) 1998-02-25 2005-07-15 Univ Emory 2-fluronucleosidos.

Also Published As

Publication number Publication date
NZ540956A (en) 2007-01-26
WO2002070533A3 (en) 2002-12-19
CA2439836A1 (en) 2002-09-12
WO2002070533A2 (en) 2002-09-12
RU2003129164A (ru) 2005-03-20
BR0207746A (pt) 2004-06-29
CN1505635A (zh) 2004-06-16
JP2004527504A (ja) 2004-09-09
IL157478A0 (en) 2004-03-28
EP1363927A2 (en) 2003-11-26
US20020198224A1 (en) 2002-12-26
AU2002255654B2 (en) 2008-05-15
US20050250946A1 (en) 2005-11-10
US6927291B2 (en) 2005-08-09
KR20030092006A (ko) 2003-12-03

Similar Documents

Publication Publication Date Title
MXPA03007853A (es) Metodo para la sintesis de 2',3'-didesoxi-2',3'-dideshidronucleosidos.
WO2002071827A3 (en) Retinoid x receptor modulators
MXPA02011370A (es) Iminoazinas substituidas.
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
PL358887A1 (en) Process for the preparation of substituted octanoyl amides
BR0113286A (pt) Pirazóis substituìdos
ZA200202568B (en) Process for the synthesis of silicoaluminophosphate molecular sieves.
TR200102338T2 (tr) Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar.
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
DK1301526T3 (da) Fremgangsmåde til oxidation til fremstilling af mellemproduktet 6.alpha.,9alpha.-difluor-11.beta.,17.alpha.-dihydroxy-16.alpha.-methyl-androst-1,4-dien-3-on 17.beta-carboxylsyre
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
DK1255747T3 (da) Syntese af 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-on
NO20024321L (no) Fremgangsmate for fremstilling av krystallinsk form I av kabergolin
EA200300579A1 (ru) Соединение лактама
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
UA66866C2 (uk) Синтез морфолінових похідних
IS2486B (is) Aralkýl-tetrahýdró-pýridín, framleiðsla þeirra oglyfjasamsetningar sem innihalda þau
WO2003035651A3 (fr) Derives de l'artemisinine, et leurs utilisations dans le traitement du paludisme
WO2004069774A3 (en) Synthesis of 13c-labelled estrogen analogues
EP1529783A3 (de) Derivative von 9,10-Dihydro-9-oxa-10-phosphaphenanthren-10-oxid
CA2258539A1 (en) Ring-fused dihydropyranes, process for the preparation and use thereof
BR0206502A (pt) Antagonistas do receptor de histamina
AU6726998A (en) Method for producing 5-aminomethyl-2-chloropyridines
ID27440A (id) Proses untuk menyiapkan penengah-penengah

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FA Abandonment or withdrawal